AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.

Data from Three Clinical Trials for Perforomist(TM) Inhalation Solution to be Presented at CHEST 2007 on October 24, 2007.

PR Newswire

| October 16, 2007 | COPYRIGHT 2007 PR Newswire Association LLC. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan.  All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)Copyright

- Presentations on long-term safety and cardiovascular safety of nebulized formoterol fumarate and safety/ efficacy of concomitant use with tiotropium for treatment of COPD -

NAPA, Calif., Oct. 16 /PRNewswire/ -- Dey, L.P., a subsidiary of Mylan Inc. , announces three clinical data presentations will be given at CHEST 2007, the annual scientific assembly of the American College of Chest Physicians (ACCP) on Wednesday, October 24, 2007 at the McCormick Place Convention Center in Chicago. Data will be presented from two safety studies that were included as part of the New Drug Application (NDA) filing to the U.S. Food and Drug Administration (FDA) for Perforomist(TM) Inhalation Solution. The third presents results from a Phase IIIb study of the concomitant use of Perforomist(TM) Inhalation Solution with tiotropium for the treatment of COPD.

Perforomist(TM) Inhalation Solution is the first and only FDA-approved nebulized form of formoterol fumarate and is indicated for long-term, twice- daily maintenance treatment of bronchoconstriction for emphysema and chronic bronchitis, also known as Chronic Obstructive Pulmonary Disease (COPD). Nebulizers convert liquid medication into a mist that patients inhale through a mouthpiece or face mask.

For those attending CHEST, the three presentations are available as follows:

 
  -- "Long-Term Safety of Nebulized Formoterol in COPD: An Open-Label 
     Active-Control Extension Study" Poster # 239 
 
  -- "Cardiovascular Safety of Nebulized Formoterol in COPD Patients: A 
     Double-Blind, Placebo-Controlled Study" Poster # 238 
 
  -- "Safety and Efficacy of Concomitant Treatment with Nebulized Formoterol 
     and Tiotropium in COPD," Poster # 251 
 
  Poster viewing: Session ID 902 - COPD Treatment II 
  Wednesday, October 24, 2007, 12:30 - 2:00 PM 
 

Convention Center, Exhibit Hall, McCormick Place, Lakeside Center, Chicago.

Clinical investigators will be available on-site to discuss the research findings.

Related articles from newspapers, magazines, journals, and more
FDA Approves Dey, L.P.'s Perforomist(TM) (Formoterol Fumarate) Inhalation...
Press release article from: PR Newswire May 11, 2007 700+ words
...worldwide use. Perforomist(TM) Inhalation Solution is the first and only FDA...fumarate, Perforomist(TM) Inhalation Solution offers a new treatment...nebulizing with Perforomist(TM) Inhalation Solution twice a day - once in the...
Mylan Inc. Subsidiary, Dey, L.P., Announces that Perforomist(TM) (Formoterol...
Press release article from: PR Newswire October 8, 2007 700+ words
...companies. Perforomist(TM) Inhalation Solution is indicated for long...experience. Perforomist(TM) Inhalation Solution is the first and only FDA...helpful that Perforomist(TM) Inhalation Solution offers a twice-daily...
New Data on Perforomist(TM) Inhalation Solution to be Presented at CHEST 2008.
Press release article from: PR Newswire October 24, 2008 700+ words
...with use of Perforomist(TM) Inhalation Solution - NAPA, Calif., Oct...results for Perforomist(TM) Inhalation Solution, twice daily via nebulization...MDI). Perforomist(TM) Inhalation Solution is approved for long...
Clinical Trial Data for Perforomist(TM) Inhalation Solution to be Presented at...
Press release article from: PR Newswire May 16, 2007 700+ words
...Nebulization Perforomist(TM) Inhalation Solution is a long-acting bronchodilator...progression. Perforomist(TM) Inhalation Solution changes the paradigm regarding...LABA such as Perforomist(TM) Inhalation Solution. For example, the clinical...
Clinical Trial Data for Perforomist(TM) Inhalation Solution to be Presented at...
Press release article from: PR Newswire May 16, 2008 700+ words
...symptoms of using Perforomist(TM) Inhalation Solution, nebulized formoterol fumarate...research results. About Perforomist(TM) Inhalation Solution Indication Perforomist(TM) Inhalation Solution is indicated for the long-term...
Critical Therapeutics and Dey, L.P. Launch Perforomist(TM) (Formoterol...
Press release article from: Business Wire October 8, 2007 700+ words
...NYSE: MYL). Perforomist[TM] Inhalation Solution is indicated for long-term, twice...United States. About Perforomist[TM] Inhalation Solution Indication Perforomist[TM] Inhalation Solution is indicated for the long-term...
Nebulized Perforomist(TM) Inhalation Solution Provided Prolonged...
Newspaper article from: Clinical Trials Week November 10, 2008 700+ words
...treatment with Perforomist(TM) Inhalation Solution nebulized formoterol fumarate...twice-daily Perforomist(TM) Inhalation Solution, nebulized FFIS, compared...with either Perforomist(TM) Inhalation Solution or albuterol/ipratropium...
Clinical Trial Data for Perforomist(TM) (Formoterol Fumarate) Inhalation...
Press release article from: PR Newswire May 20, 2007 700+ words
...found that Perforomist(TM) Inhalation Solution, a twice-daily, long...treatment between Perforomist(TM) Inhalation Solution and the active comparator...found that Perforomist(TM) Inhalation Solution was well tolerated, had...
Critical Therapeutics and Dey, L.P. Complete Definitive Co-Promotion Agreement...
Press release article from: Business Wire June 28, 2007 700+ words
...evaluations of Perforomist[TM] Inhalation Solution included two clinical trials...treated with Perforomist[TM] Inhalation Solution 20 mcg/2 mL twice daily...showed that Perforomist[TM] Inhalation Solution 20 mcg/2 mL taken twice...
BROVANA(TM) Inhalation Solution Now Available by Prescription for Patients with...
Press release article from: Business Wire April 11, 2007 700+ words
...announced that BROVANA([TM]) brand arformoterol tartrate Inhalation Solution is now available by...to be approved as an inhalation solution for use with a nebulizer...includes XOPENEX([R]) Inhalation Solution and XOPENEX HFA...
For more facts and information, see all results

Source: HighBeam Research, Data from Three Clinical Trials for Perforomist(TM) Inhalation...

©2009 Gale, a part of Cengage Learning. All rights reserved.
About us | FAQs | Contact us | Privacy policy | Terms and conditions
Other Gale sites: Encyclopedia.com | HighBeam Research | Acquire Content | Books & Authors | Goliath | MovieRetriever | Smart QandA